FUTURE 3 Study Extension

Completed · Phase 3

Conditions studied: Pulmonary Arterial Hypertension

In brief

The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).

Key facts

Study ID
NCT01338415
Run by
Actelion
People needed
58
Starts
2011-03-08
Expected to finish
2020-05-29
Last updated by the study team
2025-03-30

Who can join

Age: 0 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.